Follow us:

Microsoft Pri0

Welcome to Microsoft Pri0: That's Microspeak for top priority, and that's the news and observations you'll find here from Seattle Times technology reporter Matt Day.

June 27, 2007 at 7:03 PM

Dendreon stock gets big jolt from partnership rumors

Dendreon shares jumped 10 percent Tuesday in the wake of an analyst note that portrayed the Seattle biotech company as ripe for a lucrative partnership with Big Pharma.

Needham & Co.’s annual partnership report says that the number of partnerships in the biotech industry is poised to grow, according to Marketwatch. The report’s authors estimate Dendreon is likely to seek a partner from outside the U.S. to help with the marketing and development of Provenge, its prostate cancer-fighting drug.

The report “triggered the rumor mill,” says David Miller, an analyst at Seattle-based Biotech Stock Research. On Tuesday, Dendreon shares closed at $7.17, up 66 cents, or 10.14 percent.

Comments | More in Biotechnology

COMMENTS

No personal attacks or insults, no hate speech, no profanity. Please keep the conversation civil and help us moderate this thread by reporting any abuse. See our Commenting FAQ.



The opinions expressed in reader comments are those of the author only, and do not reflect the opinions of The Seattle Times.


The Seattle Times

The door is closed, but it's not locked.

Take a minute to subscribe and continue to enjoy The Seattle Times for as little as 99 cents a week.

Subscription options ►

Already a subscriber?

We've got good news for you. Unlimited seattletimes.com content access is included with most subscriptions.

Subscriber login ►
The Seattle Times

To keep reading, you need a subscription upgrade.

We hope you have enjoyed your complimentary access. For unlimited seattletimes.com access, please upgrade your digital subscription.

Call customer service at 1.800.542.0820 for assistance with your upgrade or questions about your subscriber status.

The Seattle Times

To keep reading, you need a subscription.

We hope you have enjoyed your complimentary access. Subscribe now for unlimited access!

Subscription options ►

Already a subscriber?

We've got good news for you. Unlimited seattletimes.com content access is included with most subscriptions.

Activate Subscriber Account ►